Fig. 1 · Structure

Documents & Downloads

Chlorprothixene

Cat. No. A10207 CAS 113-59-7
Chlorprothixene exerts strong antagonism at the following receptors: 5-HT2; D1, D2, D3; H1;mACh; α1-adrenergic.

In Stock

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Target & Activity

Target Activity Value
D2receptor ki 2.96nM
5-HT6 ki 3nM
H1receptor ki 3.75nM
D3receptor ki 4.56nM
5-HT7 ki 5.6nM
D5receptor ki 9nM
5-HT2 ki 9.4nM
D1receptor ki 18nM

8 targets · Scroll to view more

Cellular Effect

Cell Line Activity Value Description Reference
HEK293 IC50 77.8 μM Inhibition of 4-(4-(dimethylamino)styryl)-N-methylpyridinium uptake at human OCT1 expressed in HEK293 cells by confocal microscopy [PMID: 18788725]
HeLa IC50 1 nM Antagonist activity at H1 receptor in human HeLa cells assessed as inhibition of histamine-induced Ca2+ release by using fura-2AM-based fluorescence assay [PMID: 22793499]

Chlorprothixene Research Summary

This section summarizes 2 in vitro studies of Chlorprothixene from 1 published reference.

Chlorprothixene In Vitro Studies

In a purified-protein study, chlorprothixene bound the mSin3B PAH1 domain, with a reported WaterLOGSY Kd of 35 ± 11 µM. This additional binding observation does not establish cellular REST displacement. [1]

Chlorprothixene inhibited growth of DAOY medulloblastoma spheroids in a secondary concentration screen, with a reported IC50 of 9.1 µM after 6 days of incubation. The imaging endpoint combined sphere volume and optical density; it does not by itself demonstrate apoptosis or establish that PAH1 binding caused the effect. [1]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Chlorprothixene binding to the mSin3B PAH1 domain

Biochemical assay · Purified mouse Sin3B PAH1 domain (residues 28–107); GST fusion used for STD and WaterLOGSY screening. [1]

Ligand-observed NMR and protein chemical-shift perturbations supported PAH1 binding. WaterLOGSY titration gave the reported Kd. Binding alone does not establish cellular REST displacement or explain growth inhibition.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Binding to mSin3B PAH1Kd 35 ± 11 µM[1]
Protein HSQC chemical-shift changes and ligand-observed NMR signalsqualitative binding evidence YN28 showed HSQC perturbations and significant WaterLOGSY and STD signals.[1]

Literature-Reported Treatment Conditions

Treatment concentration
HSQC: 100 µM PAH1 with 100 µM or 1 mM ligand; STD/WaterLOGSY screening: 10 µM GST-PAH1 with 400 µM ligand; Kd titration: 1 µM protein and 5–50 µM ligand.
Method
NMR at 298 K; phosphate buffer pH 7.2.
Vehicle
5% DMSO for screening/HSQC samples in Methods; dilute Kd titration vehicle fraction not separately specified in Results.
Reported limits
No incubation duration, Kd ± definition, independent replicate n or direct cellular target-engagement control is established by the selected reporting.
Methods and source locations

Compound reported in the paper: Chlorprothixene; Compound label in the paper: YN28

Results concern the reported chlorprothixene material from another supplier; they do not validate A10207 lots or establish equivalent activity for salts or the trans isomer.

Figure 1a–c; Results: Evaluation of PAH1 binding affinity; Methods: NMR experiments; SI Figure S2e and Table S1 row 28

Binding to mSin3B PAH1: WaterLOGSY titration; protein 1 µM and ligand 5–50 µM as described in Results. The ± definition and replicate n are not specified in the selected reporting. — Results: Evaluation of PAH1 binding affinity by NMR titration; SI Figure S2e, YN28 (PDF p16)

Protein HSQC chemical-shift changes and ligand-observed NMR signals: HSQC with unbound protein spectrum as reference; complementary ligand-observed assays. No GST-only control is described in the selected NMR methods. — Figure 1a–c, YN28; Results: Evaluation of PAH1 binding affinity; Methods: NMR experiments

DAOY spheroid growth inhibition in the secondary concentration screen

Cell-based study · Human DAOY medulloblastoma spheroids in ultra-low attachment U-bottom plates. [1]

Chlorprothixene reduced spheroid growth in the secondary screen. The reported IC50 concerns an imaging-derived volume-sum endpoint, rather than a direct viability, apoptosis or receptor-antagonism measurement.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
DAOY spheroid growth, scored as volume sum (sphere volume and optical density)IC50 9.1 µM[1]

Literature-Reported Treatment Conditions

Treatment concentration
Secondary screen: 1, 3, 10 and 30 µM. IC50 9.1 µM is an endpoint estimate, not a treatment concentration.
Exposure duration
Compound addition on day 1; Figure 3 caption reports data after 6 days of incubation.
Method
DAOY cells seeded at 1000 cells/100 µL per well; spheroid growth monitored by imaging.
Vehicle
Figure 3 labels a 0.3% DMSO control; caption describes compound stocks in 3% DMSO before addition. No recalculated solvent fraction is substituted.
Reported limits
IC50 fitting method, IC50 uncertainty, independent biological replicate count and dose-specific vehicle matching are not specified in the selected reporting. Primary-screen concentration is internally inconsistent and is not adopted.
Methods and source locations

Compound reported in the paper: Chlorprothixene; Compound label in the paper: YN28

Results concern the reported chlorprothixene material from another supplier; they do not validate A10207 lots or establish equivalent activity for salts or the trans isomer.

Figure 3b and caption; Results: 3D growth inhibition assays of medulloblastoma; Methods: Cell culture and cancer sphere assay; SI Table S1 row 28

DAOY spheroid growth, scored as volume sum (sphere volume and optical density): Cell3iMager imaging; secondary screen after 6 days of incubation. Exact value is reported in Results, not estimated from the bars. Caption specifies triplicate wells; independent biological replicate n and IC50 uncertainty are not specified. — Results: 3D growth inhibition assays of medulloblastoma, YN28; Figure 3b and caption; Methods: Cell culture and cancer sphere assay

Specifications

Manufacturer Adooq Bioscience
CAS Number 113-59-7
Formula C18H18ClNS
Molecular Weight 315.9
Synonyms Cloxan; Taractan; Truxal
SMILES
CN(C)CC/C=C\1/C2=CC=CC=C2SC3=C1C=C(C=C3)Cl

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO 5 mg/mL (15.83 mM)
Water Insoluble
Ethanol 25 mg/mL (79.14 mM)

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Chlorprothixene Research References

  1. [1] Jun-ichi Kurita, Yuuka Hirao, Hirofumi Nakano, et al. Sertraline, chlorprothixene, and chlorpromazine characteristically interact with the REST-binding site of the corepressor mSin3, showing medulloblastoma cell growth inhibitory activities Scientific Reports (2018). PMID: 30213984 DOI: 10.1038/s41598-018-31852-1 Source material

Added to your cart

View Cart Checkout
Loading...